Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. Its innovative research attracts the attention of the investor.
As the health sector and biotechnology field continuously grow, many people gradually are curious about the next two decades of the VKTX Stock Forecast. In this blog, we will explore all key factors and expert opinions on the VKTX Stock.
Viking Therapeutics Inc (NASDAQ: VKTX)
Viking Therapeutics Inc. Is a world-famous biopharmaceutical company. Its headquarters is in California, United States, and the founders of this company are Brian Lian and Michael A. Dinerman. The founding year of this company is 2012, its primary exchange is NASDAQ, and other details of this company are given in the table below.
| Viking Therapeutics Inc. Overview | |
| Details | Information |
| Stock Name | Viking Therapeutics Inc |
| Stock Symbol | VKTX |
| Stock Exchange | NASDAQ |
| Market Cap | 3.26B USD |
| Founder | Brian Lian and Michael A. Dinerman |
| Founded Year | September 24, 2012 |
| Headquarter | California, United States |
Fundamentals of the VKTX Stock
If we are talking about the fundamentals of VKTX stock. The average trading volume is 4.01M, year revenue growth is 43.31%, and net income is -85.90M. The net income of this stock is not good because its market sentiment was not favorable.
| Stock Static | Data |
| AVG Volume | 4.01M |
| Revenue Growth % (Yearly) | 43.31% |
| Net Income in USD | -85.90M |
| ROE | – |
| EPS | -0.91 |
| P/B Ratio | 13.51 |
| P/E Ratio | – |
| Dividend Yield | – |
| Total Equity | 348.42M |
| Net profit margin | – |
| EBITDA Margin | – |
| Effective tax rate | – |
VKTX Stock Price History
Now in this paragraph, we know the VKTX stock price history. VKTX stock was listed on the NASDAQ stock exchange on 29 Apr 2015 and started from $8.00. The historical price of this stock is $85.22 and the all-time lowest price of this stock is $1.21.
| Time | Per Share Value (USD) |
| Previous close | $30.48 |
| Day Range | $29.25 – $30.70 |
| Before 5D | $29.40 |
| Before 1M | $32.87 |
| Before 6M | $66.14 |
| Before 1Y | $35.18 |
| 52 Week Range | $28.64 – $99.41 |
| Before 5Y | $6.93 |
| All time lowest | $1.21 |
| All time Max | $85.22 |
| Starting Price | $8.00 |
Major Shareholders of the VKTX Stock
The largest shareholder of this stock is Fidelity Management & Research Co. LLC which holds 14.9 % and the second major shareholder of this stock is Vanguard Fiduciary Trust Co. which holds 9.12 %
| Shareholder | Shares % |
|---|---|
| Fidelity Management & Research Co. LLC | 14.9 % |
| Vanguard Fiduciary Trust Co. | 9.12 % |
| BlackRock Advisors LLC | 4.58 % |
| State Street Corp. | 4.19 % |
| Brian Lian | 2.06 % |
Upcoming 1 to 10-Year Viking Therapeutics Stock Forecast Price Chart
Here are the coming 1 to 10-year stock forecasts table for Viking Therapeutics. This price prediction chart is based on the market experts.
| Year | Minimum Per Stock Value | Maximum Per Stock Value |
| 1 Year | $49.85 | $54.58 |
| 2 Year | $51.23 | $57.28 |
| 3 Year | $55.87 | $90.48 |
| 4 Year | $85.80 | $92.91 |
| 5 Year | $60.75 | $75.75 |
| 6 Year | $72.64 | $94.18 |
| 7 Year | $92.55 | $112.30 |
| 8 Year | $102.51 | $114.60 |
| 9 Year | $105.40 | $120.63 |
| 10 Year | $119.27 | $148.93 |
VKTX Stock Forecast 2025
VKTX stock forecast for 2025 is expected to be a minimum per stock price is $49.85 and the maximum per stock price is expected to be $54.58.
| Year | 2025 |
| Minimum Per Stock Price | $49.85 |
| Maximum per Stock Price | $54.58 |
VKTX Stock Forecast 2026
Viking Therapeutics stock forecast for 2026 is estimated to be a minimum per-stock price is $51.23 and the maximum per-stock price is estimated to be $57.28. this stock price is based on the favorable condition of the market trend.
| Year | 2026 |
| Minimum Per Stock Price | $51.23 |
| Maximum per Stock Price | $57.28 |
VKTX Stock Forecast 2027
VKTX stock forecast for 2027 is a minimum and the maximum per stock price is expected to be $55.87 to $90.48. Because Viking Therapeutics is every day discovering solutions related to metabolic and endocrine disorders disease. form this its market will increase further.
| Year | 2027 |
| Minimum Per Stock Price | $55.87 |
| Maximum per Stock Price | $90.48 |
VKTX Stock Forecast 2030
VKTX stock price forecast for 2030 minimum per stock price is expected to be $72.64 and the maximum per stock price is expected to be $94.18.
| Year | 2030 |
| Minimum Per Stock Price | $72.64 |
| Maximum per Stock Price | $94.18 |
VKTX Stock Forecast 2035
VKTX stock price forecast for 2035 is estimated price between $142.58 to $154.84.
| Year | 2035 |
| Minimum Per Stock Price | $142.58 |
| Maximum per Stock Price | $154.84 |
VKTX Stock Prediction 2025 to 2040 Chart
According to the expert, this stock in 2025 minimum per share of $49.85, and if maintains its past trend then this stock reaches the end of 2040 is $221.35.
| Year | Minimum Per Stock Value | Maximum Per Stock Value |
| 2025 | $49.85 | $54.58 |
| 2026 | $51.23 | $57.28 |
| 2027 | $55.87 | $90.48 |
| 2028 | $85.80 | $92.91 |
| 2029 | $60.75 | $75.75 |
| 2030 | $72.64 | $94.18 |
| 2035 | $142.58 | $154.84 |
| 2040 | $209.29 | $221.35 |
Challenges for Viking Therapeutics
Despite its potential, VKTX faces many challenges
1. Regulatory Hurdles: Regulatory hurdles like FDA approval are delayed, then it could impact Viking Therapeutics’ stock growth.
2. Clinical Trial Risks: Clinical trial risk could be impacting the VKTX stock price because drug development is a long and uncertain process.
3. Competition: Viking Therapeutics’ market competition is very high because many biopharmaceutical companies research similar treatments.
Checkout: Exxon Mobil Stock (XOM) Forecast From 2025 to 2040
Recent 5-Year Financial Data Chart Of The VKTX Stock
If we take a look at the revenue of this company then we can see the revenue of this company in the last 5 years is 0, and the profit of this stock is not good because this company’s last 5 years are not well.
| Year | Revenue Of VKTX Stock | VKTX Stock‘s Profit | Total Assets of VKTX Stock |
| 2020 | – | -$25.87M | $284.26M |
| 2021 | – | -$39.50M | $256.50M |
| 2022 | – | -$54.99M | $210.66M |
| 2023 | – | -$68.87M | $168.53M |
| 2024 | – | -$85.90M | $368.49M |
Final Thought of the VKTX Stock
If investors invest money for the long term in the VKTX stock then more chances to return the good amount. According to analysis and the fundamentals of this stock, Viking Therapeutics will perform well in the future because its research in the health sector and future solutions are good.
FAQs
Is Viking Therapeutics a good long-term investment?
Yes, Viking Therapeutics ‘ long-term investment is good because its future innovative research is good.
What are Viking Therapeutics’ main areas of focus?
Viking Therapeutics mainly focuses on developing treatments for metabolic and endocrine disorders.
What could drive VKTX stock growth?
Mainly driving VKTX stock growth is its innovative research like FDA approval and nd strategic partnerships.
What is the stock price forecast for VKTX in 2025?
The price forecast for 2025 is between $49.85 to $54.58. This price forecast is based on its innovative research.